Partnering
ACADIA is committed to the discovery and development of innovative treatments that address unmet medical needs in neurological and related central nervous system (CNS) disorders. Our clinical and preclinical programs all emanate from internal discoveries and are rooted in our scientific heritage and strength in CNS research.
As part of our strategy, we selectively pursue strategic collaborations to advance and maximize the commercial potential of our pipeline. In therapeutic areas that involve an extensive development program or reguire large specialty or primary care sales forces, we intend to complete late-stage development and commercialization through, or in collaboration with, partners. In areas where our products can be commercialized by a specialty sales force that calls on a limited and focused group of physicians, we plan to participate in the commercialization of our product candidates in the United States. We plan to commercialize our products in markets outside of the United States by establishing one or more strategic alliances in the future. Additionally, for discoveries we have made beyond our most advanced programs and those that have applications outside our main focus area, we may explore partnerships earlier in the process to accelerate advancements of these programs.
To further explore partnering opportunities with ACADIA, please contact us at bd@acadia-pharm.com.
Current Partnerships
ACADIA has formed three separate collaborations with Allergan in the areas of pain and ophthalmology:
The first collaboration has resulted in the discovery of alpha adrenergic drug candidates for the treatment of chronic pain.
In the second collaboration, Allergan and ACADIA are focused on the development and commercialization of selective muscarinic drugs for the treatment of glaucoma.
The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics for glaucoma and other ophthalmic conditions.
ACADIA has formed a collaboration with Meiji Seika Pharma to develop and commercialize a novel class of pro-cognitive drugs to treat patients with schizophrenia and related disorders in Japan and several other Asian countries. The collaboration is focused on developing a product candidate, AM-831, which was discovered by ACADIA. ACADIA retains the rights to develop and commercialize AM-831 in the rest of the world, including the U.S. and Europe.